Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00928811 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Safety of Chronic Administration of Simulect to Subjects Receiving a First Kidney Transplant
A Phase 2 study, sponsored by Drexel University College of Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
NCT00928811 is a Phase 2 study that was terminated before completion, run by Drexel University College of Medicine. The registered enrollment target is 5 participants.
The verdict
NCT00928811, a Phase 2 study, was terminated before completion, sponsored by Drexel University College of Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
Study Summary
The study is undertaken to explore the safety of using Simulect at monthly dose intervals to reduce the need of high dose/level CNI's such as Prograf.
Interventions
- DRUG basiliximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2009-05 |
| Est. Completion | 2010-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00928811
The ClinicalTrials.gov registry entry for NCT00928811 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Drexel University College of Medicine, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which basiliximab is the first listed.
NCT00928811 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00928811 about?
NCT00928811 is a clinical study titled "Study to Evaluate the Safety of Chronic Administration of Simulect to Subjects Receiving a First Kidney Transplant". The study is undertaken to explore the safety of using Simulect at monthly dose intervals to reduce the need of high dose/level CNI's such as Prograf.
What is the current status of trial NCT00928811?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2009-05. Estimated completion is 2010-04.
What interventions are being tested in trial NCT00928811?
The interventions under investigation include: basiliximab (DRUG).
Who is sponsoring clinical trial NCT00928811?
This trial is sponsored by Drexel University College of Medicine, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.